iQone Healthcare Switzerland focuses on advancing therapeutic options through the development and distribution of biosimilars and innovative medicines. The company emphasizes its commitment to ensuring that these therapeutic advances reach healthcare professionals and patients efficiently. iQone's portfolio includes a comprehensive range of biosimilars, particularly in the fields of oncology and immunology, with a strong emphasis on conditions such as rheumatology and gastroenterology. By leveraging in-house medical expertise and extensive local networks, iQone is able to onboard new products swiftly and facilitate their distribution across Switzerland and other European markets.

The company prides itself on building trust and maintaining strong relationships with drug manufacturers, healthcare professionals, and partners. iQone provides a full suite of services, including market studies, distribution agreements, and tailored pre- and post-sales support. Their operational model is designed to ensure that healthcare providers have access to essential medical information and training, enabling them to deliver optimal care to their patients. Additionally, iQone employs data matrices for product traceability, ensuring that healthcare professionals can manage their stocks effectively and maintain high standards of service delivery.

Switzerland

iQone Healthcare Switzerland is an independent Swiss specialty pharma company focussing on the commercialisation of biosimilars, orphan drugs and oncology products. As a Swiss company founded by leading members of the pharmaceutical industry, we have created an agile model to accelerate the transition to biosimilars. Today, the choice of biosimilars is tangible proof of physicians' commitment to the public interest. And prescribing the best available treatment at the best price is an issue of social responsibility. 

Be the actor of this paradigm shift together with us!

iQone Healthcare Switzerland

Company Details